Abstract
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of voc with or without hu hc, receiving crizanlizumab for 2 years. the efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. the approach is to extrapolate from the pk pharmacodynamics (pd) already established in the adult population. the study is designed as a phase ii, multicenter, open-label study.>
